

- Clinicians should offer assistance with partner notification and refer patients to other sources for partner notification assistance. (A2)
- Clinicians should recommend ART to all patients diagnosed with acute HIV infection. (A1)
- Clinicians should inform patients about the increased risk of transmitting HIV during acute infection and for the 6 months following infection in patients who do not initiate ART. (A2)
- As part of the initial management of patients diagnosed with acute HIV infection, clinicians should:
 - Consult with a care provider experienced in the treatment of acute HIV infection. (A3)
 - Obtain HIV genotypic resistance testing for the protease (A2), reverse transcriptase (A2), and integrase (B2) genes at the time of diagnosis.
- **Patients taking PEP:** When acute HIV infection is diagnosed in an individual receiving PEP, ART should be continued pending consultation with an experienced HIV care provider. (A3)
- **Patients taking PrEP:** Because the risk of drug-resistant mutations is higher in patients who acquire HIV while taking PrEP, clinicians should consult with an experienced HIV care provider and recommend a fully active ART regimen. (A3)
- Clinicians who do not have access to experienced HIV care providers should call the Clinical Education Initiative (CEI) Line at 866-637-2342.
- When a patient agrees with the clinician's recommendation to initiate ART during acute HIV infection:
 - The clinician should implement treatment to suppress the patient's plasma HIV RNA to below detectable levels. (A1)
 - Clinicians should perform baseline laboratory testing listed in the full guideline for all patients initiating ART immediately; ART can be started while awaiting laboratory test results. (A3)

Managing Acute HIV

Partner Notification

ALL RECOMMENDATIONS (continued from P.2)

P.3

- Clinicians should always perform a plasma HIV RNA assay in conjunction with an Ag/Ab combination immunoassay screening test. (A2)
 - Clinicians should use an Ag/Ab combination immunoassay (preferred) as the initial HIV screening test according to the standard HIV laboratory testing algorithm.
 - If the screening test is reactive, clinicians should perform an HIV-1/HIV-2 Ab differentiation immunoassay to confirm HIV infection. (A1)
 - **Note:** When rapid Ab screening is performed, even with a rapid Ag/Ab combination immunoassay, a laboratory-based Ag/Ab combination immunoassay is recommended for follow-up diagnostic HIV testing.
- ### Diagnosis
- Clinicians can presume the diagnosis of acute HIV when high levels (>10,000 copies/mL) of HIV RNA are detected in plasma with sensitive NAT, and the result of the HIV screening or type-differentiation test is negative or indeterminate. (A2)
 - When a low-level quantitative HIV RNA viral load result (<10,000 copies/mL) is obtained in the absence of serologic evidence of HIV infection, the clinician should repeat HIV RNA testing and perform an Ag/Ab combination immunoassay to exclude a false-positive result. (A2)
 - **Note:** A serologic test result that does not meet the criteria for HIV infection is a nonreactive screening result (Ab or Ag/Ab combination) or a reactive screening result with a nonreactive or indeterminate Ab differentiation confirmation result.
 - Clinicians should seek consultation when an ambiguous HIV result is obtained for an individual taking PrEP because the diagnosis of acute HIV can be particularly challenging in patients taking PrEP. (A3)
- ### ART Initiation
- If a diagnosis of acute infection is made based on HIV RNA testing, clinicians should recommend ART initiation without waiting for serologic confirmation. (A2)
 - When a pregnant individual is diagnosed with acute infection by HIV RNA testing, the clinician should wait for the result of a confirmatory test to initiate ART; initiation of ART is strongly recommended for pregnant patients. (A2)

When Acute HIV Infection Is Suspected

ALL RECOMMENDATIONS (continued from P.1)

P.2

KEY POINTS

- HIV is highly transmissible during acute infection; rapid initiation of ART reduces transmission, with significant public health benefits, and early viral suppression preserves immune function, with significant clinical benefits for the individual with HIV.
- Acute HIV often has nonspecific signs and symptoms and often goes unsuspected and undetected. This committee urges a high index of suspicion for acute infection and HIV testing for any individual who reports recent high-risk behavior or presents with signs or symptoms of influenza, mononucleosis, or other viral syndromes.
- When HIV infection is diagnosed, immediate linkage to care is essential; ART dramatically reduces HIV-related morbidity and mortality, and viral suppression prevents HIV transmission.
- The urgency of ART initiation is even greater if the newly diagnosed patient is pregnant, has acute HIV infection, is ≥50 years old, or has advanced disease. For these patients, every effort should be made to initiate ART immediately, ideally on the same day as diagnosis.
- All clinical care settings should be prepared, either on-site or with a confirmed referral, to support patients in initiating ART as rapidly as possible after diagnosis.
- When a diagnosis of acute HIV infection is made, clinicians should discuss the importance of notifying all recent contacts and refer patients to partner notification services, as mandated by New York State law. The NYSDOH can provide assistance if necessary.
- The diagnosis of acute HIV infection requires a high degree of clinical awareness. The nonspecific signs and symptoms of acute HIV infection are often not recognized or attributed to another viral illness.
- Individual laboratories have internal protocols for reporting HIV tests with preliminary results. The terms used when preliminary results cannot be classified include *indeterminate*, *inconclusive*, *nondiagnostic*, and *pending validation*. Clinicians can contact the appropriate laboratory authority to determine the significance of nondefinitive results and the recommended supplemental testing, particularly when acute HIV infection is suspected. Clinicians are advised to become familiar with the internal test-reporting policies of their institutions.

HIV CLINICAL RESOURCE 1/4-FOLDED GUIDE

VISIT HIVGUIDELINES.ORG TO LEARN MORE OR VIEW COMPLETE GUIDE



DIAGNOSIS AND MANAGEMENT OF ACUTE HIV INFECTION

NYSDOH AIDS INSTITUTE HIV CLINICAL GUIDELINE

JULY 2021

ALL RECOMMENDATIONS

P.1


NYS HIV Testing Requirements

- According to NYS law, physicians must offer an HIV test to all patients aged 13 years and older (or younger with risk) if a previous test is not documented, even in the absence of symptoms consistent with acute HIV. Although written consent to HIV testing is no longer required in NYS, patients must be given the opportunity to decline, and verbal consent must be documented in the medical record.

Presentation

- Clinicians should include acute HIV infection in the differential diagnosis for *anyone* (regardless of reported risk) who presents with signs or symptoms of influenza ("flu"), mononucleosis ("mono"), or other viral syndromes (A3), especially when the patient:
 - Presents with a rash. (A2)
 - Requests HIV testing. (A3)
 - Reports recent sexual or parenteral exposure to a person with or at risk of HIV infection. (A2)
 - Presents with a newly diagnosed STI. (A2)
 - Presents with aseptic meningitis. (A2)
 - Is pregnant or breastfeeding. (A3)
 - Is currently taking antiretroviral medications for PrEP or PEP. (A3)
- Diagnostic HIV RNA testing should be considered for patients who present with compatible symptoms (see Box 1: Acute Retroviral Syndrome), particularly in the presence of an STI or a recent sexual or parenteral exposure with a partner known to have HIV or with unknown HIV serostatus. (A2)

FIGURE 2. Diagnostic Testing for Acute HIV Infection



BOX 1: ACUTE RETROVIRAL SYNDROME

Signs and symptoms of ARS with the expected frequency among symptomatic patients are listed below [a]. The most specific symptoms in this study were oral ulcers and weight loss; the best predictors were fever and rash. The index of suspicion should be high when these symptoms are present.

- Fever (80%)
- Tired or fatigued (78%)
- Malaise (68%)
- Arthralgias (joint pain) (54%)
- Headache (54%)
- Loss of appetite (54%)
- Rash (51%)
- Night sweats (51%)
- Myalgias (pain in muscles) (49%)
- Nausea (49%)
- Diarrhea (46%)
- Fever and rash (46%)
- Pharyngitis (sore throat) (44%)
- Oral ulcers (mouth sores) (37%)
- Stiff neck (34%)
- Weight loss (>5 lb; 2.5 kg) (32%)
- Confusion (25%)
- Photophobia (24%)
- Vomiting (12%)
- Infected gums (10%)
- Sores on anus (5%)
- Sores on genitals (2%)

a. Data are from Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. *AIDS* 2002;16(8):1119–1129. [PMID: 12004270]

Notes:

- a. Viremia will be present several days before antibody detection.
- b. The absence of serologic evidence of HIV infection is defined as nonreactive screening result (antibody or antibody/antigen combination) or a reactive screening result with a nonreactive or indeterminate antibody–differentiation confirmatory result.
- c. Serologic confirmation as defined by the CDC HIV testing algorithm. Western blot is no longer recommended as the confirmatory test because it may yield an indeterminate result during the early stages of seroconversion and may delay confirmation of diagnosis.
- d. No further testing is indicated.



← Use this code with your phone's QR code reader to go directly to a mobile-friendly version of the guideline.

■ This 1/4-Folded Guide is a companion to the New York State Department of Health AIDS Institute guideline *Diagnosis and Management of Acute HIV*. The full guideline is available at www.hivguidelines.org.